Age-related macular degeneration

The Lancet

Volumn 392, Issue 10153, 2018, Pages 1147-1159

  Mitchell, Paul ^a   Liew, Gerald ^a   Gopinath, Bamini ^a   Wong, Tien Y ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTIOXIDANT; BEVACIZUMAB; CAROTENOID; RANIBIZUMAB; VERTEPORFIN; VITAMIN; ZINC; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; ARMS2 GENE; CFH GENE; COMPLEMENT SYSTEM; DIETARY INTAKE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESEARCH; EXTRACELLULAR MATRIX; GENE; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LIPID METABOLISM; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DISEASE EXACERBATION; INCIDENCE; MACULAR DEGENERATION;

DISEASE PROGRESSION; HUMANS; INCIDENCE; MACULAR DEGENERATION; PREVALENCE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85053849614     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31550-2     Document Type: Review

References (139)

1. Coleman, HR, Chan, CC, Ferris, FL 3rd, Chew, EY, Age-related macular degeneration. Lancet 372 (2008), 1835–1845.
2. Lim, LS, Mitchell, P, Seddon, JM, Holz, FG, Wong, TY, Age-related macular degeneration. Lancet 379 (2012), 1728–1738.
3. Wong, WL, Su, X, Li, X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2 (2014), e106–e116.
4. Bourne, RR, Stevens, GA, White, RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health 1 (2013), e339–e349.
5. Cicinelli, MV, Rabiolo, A, Sacconi, R, et al. Optical coherence tomography angiography in dry age-related macular degeneration. Surv Ophthalmol 63 (2018), 236–244.
6. Sambhav, K, Grover, S, Chalam, KV, The application of optical coherence tomography angiography in retinal diseases. Surv Ophthalmol 62 (2017), 838–866.
7. Schmidt-Erfurth, U, Klimscha, S, Waldstein, SM, Bogunović H, A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond) 31 (2017), 26–44.
8. Bird, AC, Bressler, NM, Bressler, SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 39 (1995), 367–374.
9. Ferris, FL 3rd, Wilkinson, CP, Bird, A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 120 (2013), 844–851.
10. Klein, R, Meuer, SM, Myers, CE, et al. Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium. Ophthalmic Epidemiol 21 (2014), 14–23.
11. Davis, MD, Gangnon, RE, Lee, LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 123 (2005), 1484–1498.
12. Ferris, FL, Davis, MD, Clemons, TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 123 (2005), 1570–1574.
13. Liew, G, Joachim, N, Mitchell, P, Burlutsky, G, Wang, JJ, Validating the AREDS Simplified Severity Scale of age-related macular degeneration with 5- and 10-year incident data in a population-based sample. Ophthalmology 123 (2016), 1874–1878.
14. Joachim, N, Mitchell, P, Kifley, A, Rochtchina, E, Hong, T, Wang, JJ, Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology 120 (2013), 2042–2050.
15. Zhou, Q, Daniel, E, Maguire, MG, et al. Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials. Ophthalmology 123 (2016), 1530–1540.
16. Finger, RP, Wu, Z, Luu, CD, et al. Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology 121 (2014), 1252–1256.
17. Khan, KN, Mahroo, OA, Khan, RS, et al. Differentiating drusen: drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin Eye Res 53 (2016), 70–106.
18. Smith, W, Assink, J, Klein, R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108 (2001), 697–704.
19. Joachim, N, Mitchell, P, Burlutsky, G, Kifley, A, Wang, JJ, The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains Eye Study. Ophthalmology 122 (2015), 2482–2489.
20. Colijn, JM, Buitendijk, GHS, Prokofyeva, E, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology 124 (2017), 1753–1763.
21. Cruickshanks, KJ, Nondahl, DM, Johnson, LJ, et al. Generational differences in the 5-year incidence of age-related macular degeneration. JAMA Ophthalmol 135 (2017), 1417–1423.
22. Lambert, NG, ElShelmani, H, Singh, MK, et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res 54 (2016), 64–102.
23. Mitchell, P, Wang, JJ, Smith, W, Leeder, SR, Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 120 (2002), 1357–1363.
24. Adams, MK, Chong, EW, Williamson, E, et al. 20/20—alcohol and age-related macular degeneration: the Melbourne Collaborative Cohort Study. Am J Epidemiol 176 (2012), 289–298.
25. Shankar, A, Mitchell, P, Rochtchina, E, Tan, J, Wang, JJ, Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Am J Epidemiol 165 (2007), 375–382.
26. Kauppinen, A, Paterno, JJ, Blasiak, J, Salminen, A, Kaarniranta, K, Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 73 (2016), 1765–1786.
27. Casparis, H, Lindsley, K, Kuo, IC, Sikder, S, Bressler, NM, Surgery for cataracts in people with age-related macular degeneration. Cochrane Database Syst Rev, 2, 2017 CD006757.
28. Cheung, CM, Wong, TY, Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. J Intern Med 276 (2014), 140–153.
29. Pennington, KL, DeAngelis, MM, Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond), 3, 2016, 34.
30. Kabasawa, S, Mori, K, Horie-Inoue, K, et al. Associations of cigarette smoking but not serum fatty acids with age-related macular degeneration in a Japanese population. Ophthalmology 118 (2011), 1082–1088.
31. Brody, BL, Gamst, AC, Williams, RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 108 (2001), 1893–1901.
32. Casten, RJ, Rovner, BW, Update on depression and age-related macular degeneration. Curr Opin Ophthalmol 24 (2013), 239–243.
33. Mitchell, J, Bradley, C, Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes, 4, 2006, 97.
34. Gopinath, B, Liew, G, Burlutsky, G, Mitchell, P, Age-related macular degeneration and 5-year incidence of impaired activities of daily living. Maturitas 77 (2014), 263–266.
35. Wood, JM, Lacherez, P, Black, AA, Cole, MH, Boon, MY, Kerr, GK, Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Invest Ophthalmol Vis Sci 52 (2011), 5088–5092.
36. Woo, SJ, Park, KH, Ahn, J, et al. Cognitive impairment in age-related macular degeneration and geographic atrophy. Ophthalmology 119 (2012), 2094–2101.
37. Tsai, DC, Chen, SJ, Huang, CC, Yuan, MK, Leu, HB, Age-related macular degeneration and risk of degenerative dementia among the elderly in Taiwan: a population-based cohort study. Ophthalmology, 122, 2015, 2327 35.e2.
38. Keenan, TD, Goldacre, R, Goldacre, MJ, Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 132 (2014), 63–68.
39. McGuinness, MB, Karahalios, A, Finger, RP, Guymer, RH, Simpson, JA, Age-related macular degeneration and mortality: a systematic review and meta-analysis. Ophthalmic Epidemiol 24 (2017), 141–152.
40. Fritsche, LG, Fariss, RN, Stambolian, D, Abecasis, GR, Curcio, CA, Swaroop, A, Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 15 (2014), 151–171.
41. Cipriani, V, Leung, HT, Plagnol, V, et al. Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3. Hum Mol Genet 21 (2012), 4138–4150.
42. Holliday, EG, Smith, AV, Cornes, BK, et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis. PLoS One, 8, 2013, e53830.
43. Fritsche, LG, Igl, W, Bailey, JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 48 (2016), 134–143.
44. Whitmore, SS, Sohn, EH, Chirco, KR, et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45 (2015), 1–29.
45. SanGiovanni, JP, Chew, EY, Clinical applications of age-related macular degeneration genetics. Cold Spring Harb Perspect Med, 4, 2014, a017228.
46. Gliem, M, Müller, PL, Mangold, E, et al. Sorsby fundus dystrophy: novel mutations, novel phenotypic characteristics, and treatment outcomes. Invest Ophthalmol Vis Sci 56 (2015), 2664–2676.
47. Chiu, CJ, Mitchell, P, Klein, R, et al. A risk score for the prediction of advanced age-related macular degeneration: development and validation in 2 prospective cohorts. Ophthalmology 121 (2014), 1421–1427.
48. Seddon, JM, Reynolds, R, Yu, Y, Daly, MJ, Rosner, B, Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 118 (2011), 2203–2211.
49. Buitendijk, GH, Rochtchina, E, Myers, C, et al. Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology 120 (2013), 2644–2655.
50. American Academy of Ophthalmology. Age-related macular degeneration PPP—updated. https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015, 2015. (Accessed 16 September 2018)
51. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309 (2013), 2005–2015.
52. Seddon, JM, Francis, PJ, George, S, Schultz, DW, Rosner, B, Klein, ML, Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 297 (2007), 1793–1800.
53. Seddon, JM, Reynolds, R, Shah, HR, Rosner, B, Smoking, dietary betaine, methionine, and vitamin D in monozygotic twins with discordant macular degeneration: epigenetic implications. Ophthalmology 118 (2011), 1386–1394.
54. Curcio, CA, Messinger, JD, Sloan, KR, McGwin, G, Medeiros, NE, Spaide, RF, Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, prevalence, topography, and biogenesis model. Retina 33 (2013), 265–276.
55. Rudolf, M, Clark, ME, Chimento, MF, Li, CM, Medeiros, NE, Curcio, CA, Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy. Invest Ophthalmol Vis Sci 49 (2008), 1200–1209.
56. Green, WR, Histopathology of age-related macular degeneration. Mol Vis, 5, 1999, 27.
57. Li, CM, Clark, ME, Rudolf, M, Curcio, CA, Distribution and composition of esterified and unesterified cholesterol in extra-macular drusen. Exp Eye Res 85 (2007), 192–201.
58. Curcio, CA, Johnson, M, Huang, JD, Rudolf, M, Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res 28 (2009), 393–422.
59. Sarks, S, Cherepanoff, S, Killingsworth, M, Sarks, J, Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 48 (2007), 968–977.
60. Gass, JDM, Stereoscopic atlas of macular diseases. 4th edn., 1998, Mosby, St Louis.
61. Freund, KB, Ho, IV, Barbazetto, IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28 (2008), 201–211.
62. Yannuzzi, LA, Negrão, S, Iida, T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 21 (2001), 416–434.
63. Tsai, ASH, Cheung, N, Gan, ATL, et al. Retinal angiomatous proliferation. Surv Ophthalmol 62 (2017), 462–492.
64. Wong, CW, Yanagi, Y, Lee, WK, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53 (2016), 107–139.
65. McLeod, DS, Grebe, R, Bhutto, I, Merges, C, Baba, T, Lutty, GA, Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci 50 (2009), 4982–4991.
66. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119 (2001), 1417–1436.
67. Chew, EY, Clemons, TE, Sangiovanni, JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 132 (2014), 142–149.
68. Ma, L, Dou, HL, Wu, YQ, et al. Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis. Br J Nutr 107 (2012), 350–359.
69. Tan, JSL, Wang, JJ, Flood, V, Rochtchina, E, Smith, W, Mitchell, P, Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 115 (2008), 334–341.
70. Zhu, W, Wu, Y, Meng, YF, Xing, Q, Tao, JJ, Lu, J, Fish consumption and age-related macular degeneration incidence: a meta-analysis and systematic review of prospective cohort studies. Nutrients, 8, 2016, E743.
71. Chew, EY, Clemons, TE, Agrón, E, et al. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology, 120, 2013, 1604 11.e4.
72. Lawrenson, JG, Evans, JR, Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev, 11, 2012 CD010015.
73. Shweiki, D, Itin, A, Soffer, D, Keshet, E, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992), 843–845.
74. Gragoudas, ES, Adamis, AP, Cunningham, ET Jr, Feinsod, M, Guyer, DR, Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004), 2805–2816.
75. Rosenfeld, PJ, Brown, DM, Heier, JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
76. Brown, DM, Kaiser, PK, Michels, M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1432–1444.
77. Heier, JS, Brown, DM, Chong, V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
78. Martin, DF, Maguire, MG, Fine, SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119 (2012), 1388–1398.
79. Chakravarthy, U, Harding, SP, Rogers, CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382 (2013), 1258–1267.
80. Kodjikian, L, Souied, EH, Mimoun, G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 120 (2013), 2300–2309.
81. Schauwvlieghe, AM, Dijkman, G, Hooymans, JM, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD Study. PLoS One, 11, 2016, e0153052.
82. Ho, AC, Busbee, BG, Regillo, CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121 (2014), 2181–2192.
83. Wykoff, CC, Croft, DE, Brown, DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122 (2015), 2514–2522.
84. Berg, K, Pedersen, TR, Sandvik, L, Bragadóttir, R, Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122 (2015), 146–152.
85. Li, X, Xu, G, Wang, Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121 (2014), 1740–1747.
86. Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD). https://www.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients, Dec 12, 2016. (Accessed 16 September 2018)
87. Dugel, PU, Jaffe, GJ, Sallstig, P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 124 (2017), 1296–1304.
88. Csaky, KG, Dugel, PU, Pierce, AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology 122 (2015), 579–588.
89. Yaspan, BL, Williams, DF, Holz, FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med, 9, 2017, eaaf1443.
90. Jaffe, GJ, Schmitz-Valckenberg, S, Boyer, D, et al. Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE study. Am J Ophthalmol 160 (2015), 1226–1234.
91. Yehoshua, Z, de Amorim Garcia Filho, CA, Nunes, RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 121 (2014), 693–701.
92. Michels, S, Rosenfeld, PJ, Puliafito, CA, Marcus, EN, Venkatraman, AS, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005), 1035–1047.
93. Rosenfeld, PJ, Moshfeghi, AA, Puliafito, CA, Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005), 331–335.
94. Solomon, SD, Lindsley, KB, Krzystolik, MG, Vedula, SS, Hawkins, BS, Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane systematic review. Ophthalmology 123 (2016), 70–77.e1.
95. Waldstein, SM, Simader, C, Staurenghi, G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 123 (2016), 1521–1529.
96. Stoller, GL, Kokame, GT, Dreyer, RF, Shapiro, H, Tuomi, LL, Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration. JAMA Ophthalmol 134 (2016), 545–553.
97. Johnston, RL, Carius, HJ, Skelly, A, Ferreira, A, Milnes, F, Mitchell, P, A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom. Adv Ther 34 (2017), 703–712.
98. Berg, K, Hadzalic, E, Gjertsen, I, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results. Ophthalmology 123 (2016), 51–59.
99. Arnold, JJ, Campain, A, Barthelmes, D, et al. Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 122 (2015), 1212–1219.
100. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121 (2014), 1092–1101.
101. Rofagha, S, Bhisitkul, RB, Boyer, DS, Sadda, SR, Zhang, K, Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120 (2013), 2292–2299.
102. Maguire, MG, Martin, DF, Ying, GS, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123 (2016), 1751–1761.
103. Zarranz-Ventura, J, Liew, G, Johnston, RL, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology 121 (2014), 1966–1975.
104. Bhisitkul, RB, Desai, SJ, Boyer, DS, Sadda, SR, Zhang, K, Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology 123 (2016), 1269–1277.
105. Bloch, SB, Larsen, M, Munch, IC, Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153 (2012), 209–213.e2.
106. Borooah, S, Jeganathan, VS, Ambrecht, AM, et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond) 29 (2015), 1156–1161.
107. Johnston, RL, Lee, AY, Buckle, M, et al. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology 123 (2016), 2386–2392.
108. Wong, TY, Chakravarthy, U, Klein, R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115 (2008), 116–126.
109. Holz, FG, Tadayoni, R, Beatty, S, et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye (Lond) 30 (2016), 1063–1071.
110. Gillies, MC, Nguyen, V, Daien, V, Arnold, JJ, Morlet, N, Barthelmes, D, Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology 123 (2016), 2545–2553.
111. Koh, A, Lai, TYY, Takahashi, K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 135 (2017), 1206–1213.
112. Cheung, CMG, Lai, TYY, Ruamviboonsuk, P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 125 (2018), 708–724.
113. Lee, WK, Ogura, Y, Iida, T, et al. Efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculopathy: 12-month results of the PLANET study. Invest Ophthalmol Vis Sci, 58, 2017, 1199.
114. Lee, WK, Iida, T, Ogura, Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol, 2018 published online May 2. DOI:10.1001/jamaophthalmol.2018.1804.
115. Ueta, T, Noda, Y, Toyama, T, Yamaguchi, T, Amano, S, Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. Ophthalmology, 121, 2014, 2193 203.e1–7.
116. Yashkin, AP, Hahn, P, Sloan, FA, Introducing anti-vascular endothelial growth factor therapies for AMD did not raise risk of myocardial infarction, stroke, and death. Ophthalmology 123 (2016), 2225–2231.
117. Meredith, TA, McCannel, CA, Barr, C, et al. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 122 (2015), 817–821.
118. Holz, FG, Strauss, EC, Schmitz-Valckenberg, S, van Lookeren Campagne, M, Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 121 (2014), 1079–1091.
119. Kimel, M, Leidy, NK, Tschosik, E, et al. Functional reading independence (FRI) index: a new patient-reported outcome measure for patients with geographic atrophy. Invest Ophthalmol Vis Sci 57 (2016), 6298–6304.
120. Schaal, KB, Rosenfeld, PJ, Gregori, G, Yehoshua, Z, Feuer, WJ, Anatomic clinical trial endpoints for nonexudative age-related macular degeneration. Ophthalmology 123 (2016), 1060–1079.
121. Boyer, DS, Schmidt-Erfurth, U, van Lookeren Campagne, M, Henry, EC, Brittain, C, The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina 37 (2017), 819–835.
122. Holz, FG, Sadda, SR, Busbee, B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri Phase 3 randomized clinical trials. JAMA Ophthalmol 136 (2018), 666–677.
123. Holz, FG, Dugel, PU, Weissgerber, G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology 123 (2016), 1080–1089.
124. Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval. https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients, Jun 20, 2017. (Accessed 16 September 2018)
125. Strittmatter, K, Pomeroy, H, Marneros, AG, Targeting platelet-derived growth factor receptor β(+) scaffold formation inhibits choroidal neovascularization. Am J Pathol 186 (2016), 1890–1899.
126. Jaffe, GJ, Eliott, D, Wells, JA, Prenner, JL, Papp, A, Patel, S, A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology 123 (2016), 78–85.
127. Jaffe, GJ, Ciulla, TA, Ciardella, AP, et al. Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial. Ophthalmology 124 (2017), 224–234.
128. Dunn, EN, Hariprasad, SM, Sheth, VS, An overview of the Fovista and Rinucumab trials and the fate of anti-PDGF medications. Ophthalmic Surg Lasers Imaging Retina 48 (2017), 100–104.
129. Ratnapriya, R, Chew, EY, Age-related macular degeneration—clinical review and genetics update. Clin Genet 84 (2013), 160–166.
130. Guymer, RH, Baird, PN, Varsamidis, M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. PLoS One, 8, 2013, e83759.
131. Miller, JW, Beyond VEGF-the Weisenfeld lecture. Invest Ophthalmol Vis Sci 57 (2016), 6911–6918.
132. Gehlbach, P, Li, T, Hatef, E, Statins for age-related macular degeneration. Cochrane Database Syst Rev, 2015 CD006927.
133. MacLaren, RE, Bennett, J, Schwartz, SD, Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology 123 (2016), S98–S106.
134. Constable, IJ, Lai, CM, Magno, AL, et al. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol 177 (2017), 150–158.
135. Rakoczy, EP, Lai, CM, Magno, AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386 (2015), 2395–2403.
136. Nazari, H, Zhang, L, Zhu, D, et al. Stem cell based therapies for age-related macular degeneration: the promises and the challenges. Prog Retin Eye Res 48 (2015), 1–39.
137. Grzybowski, A, Wasinska-Borowiec, W, Alio, JL, Amat-Peral, P, Tabernero, J, Intraocular lenses in age-related macular degeneration. Graefes Arch Klin Exp Ophthalmol 255 (2017), 1687–1696.
138. da Cruz, L, Dorn, JD, Humayun, MS, et al. Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial. Ophthalmology 123 (2016), 2248–2254.
139. Stingl, K, Schippert, R, Bartz-Schmidt, KU, et al. Interim results of a multicenter trial with the new electronic subretinal implant Alpha AMS in 15 patients blind from inherited retinal degenerations. Front Neurosci, 11, 2017, 445.